Computed tomography measures of nutrition in patients with end-stage liver disease provide a novel approach to characterize deficits by Bush, Weston J. et al.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
TITLE PAGE 
Title: Computed tomography measures of nutrition in patients with end-stage liver disease 
provide a novel approach to characterize deficits   
Submitted as an original work. 
Authors: Weston J Bush, Jason P Davis, Mary A Maluccio, Chandrashekhar A Kubal, Jared B 
Salisbury, Richard S Mangus 
For all: Transplant Division, Department of Surgery, Indiana University, School of Medicine, 
Indianapolis, USA 
E-mail addresses of authors: wjbush@iupui.edu; Jason.davis.p@gmail.com;
mmalucci@iupui.edu; sakubal@iupui.edu; jbsalisb@indiana.edu; rmangus@iupui.edu 
Corresponding author: Richard S. Mangus, MD MS FACS; 550 North University Blvd, Room 
4601; Indianapolis, Indiana, 46077, USA. Electronic mail: rmangus@iupui.edu 
Phone: +1 (317) 919-6734 
Grant information: This research received no outside funding. 
Key words: Sarcopenia, end-stage liver disease, liver transplant, malnutrition, frailty 
Abbreviations: 
ESLD, end-stage liver disease; BMI, body mass index; MELD, model for end-stage liver 
disease; CT, computed tomography; ANOVA, analysis of variance; SPSS, Statistical package for 
the Social Sciences. 
Tables: 5 (demographics and outcomes, subgroup analyses by MELD, gender, age, and BMI) 
Figures: 1 (CT figure with color) 
Manuscript word count: 2525 
Abstract word count: 246 
Running head: Sarcopenia in End-stage Liver Disease Patients 
___________________________________________________________________
This is the author's manuscript of the article published in final edited form as:
Bush, W. J., Davis, J. P., Maluccio, M. A., Kubal, C. A., Salisbury, J. B., & Mangus, R. S. (2018). Computed tomography 
measures of nutrition in patients with end-stage liver disease provide a novel approach to characterize deficits. 
Transplantation Proceedings. https://doi.org/10.1016/j.transproceed.2018.06.006
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Abstract 
Aim: Patients with cirrhosis and end-stage liver disease (ESLD) develop severe nutrition deficits that 
impact on morbidity and mortality. Laboratory measures of nutrition fail to fully assess clinical deficits in 
muscle mass and fat stores. This study employs computed tomography imaging to assess muscle mass 
and subcutaneous and visceral fat stores in patients with ESLD. 
Methods: This 1:1 case-control study design compares ESLD patients with healthy controls.  Study 
patients were selected from a database of ESLD patients using a stratified method to assure a 
representative sample based on age, body mass index (BMI), gender, and model for end-stage liver 
disease score (MELD). Control patients were trauma patients with a low injury severity score (<10) who 
had a CT scan during evaluation. Cases and controls were matched for age +/- 5 years, gender, and BMI 
+/- 2. 
Results: There were 90 subjects and 90 controls.  ESLD patients had lower albumin levels (p<0.001), but 
similar total protein levels (p=0.72). ESLD patients had a deficit in muscle mass (-19%, p<0.001) and 
visceral fat (-13%, p<0.001), but similar subcutaneous fat (-1%, p=0.35). ESLD patients at highest risk 
for sarcopenia included those over age 60, BMI< 25.0, and female gender. We found degree of sarcopenia 
to be independent of MELD score. 
Conclusions: These results support previous research demonstrating substantial nutrition deficits in 
ESLD patients that are not adequately measured by laboratory testing. Patients with ESLD have 
significant deficits of muscle and visceral fat stores, but a similar amount of subcutaneous fat. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
1 
 
INTRODUCTION 
  Frailty is a biologic syndrome of decreased physiologic reserve and resistance to stressors, 
resulting from cumulative declines across multiple physiologic systems, and causing vulnerability to 
adverse outcomes.[1] Sarcopenia, or muscle wasting, is an indicator of frailty in chronically ill and elderly 
patients. The theoretic etiologies of sarcopenia include malnutrition or malabsorption, increased 
myostatin (aging), abnormal use of protein as an energy source (cirrhosis), hormone deficiencies 
(cirrhosis), and reduced branched-chain amino acids (hepatic encephalopathy).[2] Liver disease is 
associated with many physiological changes such as altered metabolism and hormone imbalances 
resulting in a high risk for developing severe muscle wasting and frailty.[2-4] Sarcopenia is common 
among liver transplant candidates.[5, 6]  Recent studies have shown an association between sarcopenia 
and adverse outcomes in chronically ill patients, including increased length of hospitalization, number of 
complications, health care costs, and mortality.[3, 7-13]   Poor outcomes specific for ESLD patients 
include increased waitlist mortality, post-transplant mortality, length of post-transplant hospitalization, 
and infection.[8, 13-15]   
 There are multiple techniques to measure total body composition, including sarcopenia.  Dual X-
ray absorptiometry is the gold standard for measuring body composition in patients without fluid overload 
or ascites.[16-18] This tool, therefore, is not a reliable measure of total body composition in the patient 
with end-stage liver disease.  Single slice axial computed tomography (CT) measurements of core muscle 
mass, visceral fat and subcutaneous fat have been shown to be accurate predictors of total body muscle 
and fat composition and may be used to predict changes in nutrition status in the transplant 
population.[19-23] MELD score, age, and BMI are all considered when deciding if a patient with ESLD 
is an acceptable candidate for transplantation.  Frailty as a risk-factor of morbidity and mortality has 
largely been excluded from the discussion. This study was designed to quantify the severity of sarcopenia 
in ESLD patients, and to analyze the association between sarcopenia and BMI, age, gender, and MELD in 
ESLD patients. 
METHODS 
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Records from a single center transplant database of 644 adults (≥18 years old) with ESLD who 
received a transplant between 2009-2014 were used for this study.  Patients in this database were 
stratified by groups according to MELD, age and gender. Patients were first classified into three MELD 
groupings for scores <20, 20-30, and >30.  Each of these MELD group was then stratified by age groups 
of 18-39, 40-49, 50-59, and 60+ years.  Finally, 6 males and 6 females were randomly selected from each 
MELD-age group using a randomizer.  If there were less than 6 males or 6 females in any group, then all 
of the available patients were chosen for study inclusion. This selection process resulted in a pool of 133 
patients.  Of the 133 randomly selected patients, 99 had an abdominal CT within 90 days before 
transplant, and 90 patients could be matched to a healthy control patient.  Control patient data were 
extracted from a large trauma database within our health system, in order to perform a 1:1 case-control 
study design.  Each anonymous qualifying control had an injury severity score less than 10 and received 
an abdominal CT scan during their initial trauma presentation and evaluation.  Case-control matching 
criteria included the control being +/- 5 years, +/- 2.0 BMI, and the same gender as the case.  
 To assess for sarcopenia, CT imaging was used because it is standard practice for patients 
awaiting liver transplantation to receive an abdominal CT, and core muscle measurements from CT have 
been shown to be an acceptable indicator of total body muscle mass.[19-23] For each case and control, 
measurements of total psoas muscle area and subcutaneous fat area were taken at the most superior aspect 
of L3.  Measurements at this level are accurate indicators of total body composition.[19, 22]  Visceral fat 
is represented by perinephric fat and was measured at the hilum of the kidney.  Three research assistants, 
who were trained in reading abdomen CT scans, made each measurement blind to the measurements of 
the other assistants and to the diagnosis and outcome of the patient.  This was done to establish inter-rater 
reliability.  Any measurement that differed by >15% of the mean (of the three readers) was re-examined 
until a consensus was reached.  The mean of all three measurements was used to minimize the human 
error of each measurement.  Total psoas area, total subcutaneous fat, and total visceral fat were scaled for 
the height of the patient by dividing the measured area (in cm2) by the height (in meter2). This created the 
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muscle index (derived from the total psoas area), subcutaneous fat index, and the visceral fat index 
(derived from perinephric fat) used in the comparison between case and control. 
 To make each measurement, the imaging software was set to “soft tissue” and the free hand 
drawing tool was used.  [Figure] To measure the total psoas muscle area, the left and right psoas muscles 
were outlined at the most superior L3 CT slice and the two areas were summed to get the combined total 
psoas area.  The subcutaneous fat area was obtained by subtracting the area of the outlined abdominal 
cavity (at the outermost muscle layer) from the area outlined just under the dermis.  Visceral fat was 
assessed by measuring the perinephric fat. Since the level of the kidney within the abdominal cavity 
differed for each patient, the measurements were taken at the hilum of each individual kidney.  This was 
done by outlining the kidney and vasculature and subtracting this area from the area obtained by outlining 
Gerota’s fascia.  Total visceral fat was calculated by summing the right and left perinephric fat values.  
 CT images were viewed and measured using Synapse picture archiving and communication 
system (PACS) software (FUJIFILM Holdings America Corporation, Valhalla, New York, USA). Data 
were analyzed using Statistical Package for the Social Sciences (IBM SPSS Statistics 24, IBM 
Corporation, Armonk, New York, USA). Retrospective analysis of patient data for this study were 
reviewed and approved by the Institutional Review Board of the Indiana University School of Medicine 
(study number 1011003619R005). Categorical variables in the analysis were compared using chi-square 
analysis, and continuous variable were compared using standard analysis of variance testing (ANOVA). 
Results with p-value <0.05 were considered statistically significant. 
RESULTS 
 The median age and BMI of the 90 study patients was 45 and 27.2, respectively.  Of these 90 
patients, 52 of them were male.  Likewise, the controls had a median age and BMI of 46 and 27.8, 
respectively. [Table 1]  There was not a difference between the groups in total serum protein, but a 
deficiency in serum albumin was noted in ESLD patients (2.9 versus 3.6, p <0.001).  A grouped analysis, 
comparing the medians between all cases and controls, was performed and showed a deficit in muscle 
mass index (42 ESLD versus 52 controls, p<0.001) and a deficit in visceral fat index (71 ESLD versus 
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114 controls, p<0.001). There was no difference in subcutaneous fat index (551 ESLD and 591 controls, 
p=0.35).  Additionally, a matched analysis was done where the percent difference between each case and 
control was calculated. The median percent difference between each case and control included a 19% 
deficit in muscle mass index, a 13% deficit in visceral fat index, but an inconsequential 1 % difference in 
subcutaneous fat index.   
This study was designed to analyze muscle mass and fat differences among patients stratified by 
BMI, gender, age and MELD score. The first subgroup analysis was stratified by BMI groupings (<25, 
25-29, 30-34, 35+). [Table 2] Muscle mass index, subcutaneous fat index, and visceral fat index all 
differed among BMI groups with each index increasing with increased BMI (p= 0.03, <0.001, 0.02 
respectively).  BMI <25 had the most profound sarcopenia with a 29% muscle mass index deficit when 
compared to age-gender-BMI-matched controls.  Muscle mass deficits also existed in the 25-29 and 30-34 
BMI groupings with a -22% and -16% difference when compared to controls. The muscle mass index for 
ESLD patients was 9% higher than controls in the highest grouping of BMI ≥35.  The highest BMI group 
also showed ESLD patients with a 7% higher subcutaneous fat and 34% less visceral fat than controls.  
While the visceral fat index increased with increasing BMI (56, 74, 83, 110), the matched analysis 
showed greater deficits in visceral fat among increasing BMI groupings.  BMI groupings of 30-34 and 
≥35 showed greater deficiencies in visceral fat than those with BMI <30 (-27% and -34% versus -12%). 
There were only minimal differences in the laboratory measures (serum albumin and protein) between 
BMI groups, which failed to reach significance. 
 Subgroup analysis by gender included data on 52 males and 38 females. [Table 3] Both genders 
had a similar deficit in serum albumin compared to controls (p=0.25), but females with ESLD had a 
higher serum protein level when compared to ESLD males and the combined control group (p<0.01). The 
ESLD female group had significantly lower muscle mass when compared to both the combined control 
group and to the ESLD male group (p<0.001). The female group also had a higher subcutaneous fat index 
(p<0.001) and a lower visceral fat index (p<0.001).   
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 Subgroup analysis by age included comparison of four age groups (18-39, 40-49, 50-59, ≥60). 
[Table 4] The serum albumin and total protein were similar among all age groups, with all ESLD patients 
having low albumin levels compared to the control group. The psoas area index was lower for all age 
groups when compared to the control group (p=0.05). Among ESLD patients, the group over age 60 had a 
markedly lower muscle mass index when compared to all other patients. Differences in the subcutaneous 
fat index were insignificant between age groups. Visceral fat index increased with each age group starting 
at 53 for the ages 18-39 grouping and rising to 90 in the ≥60 age group (p= <0.001).  Patients over age 60 
also had the greatest visceral fat deficits when compared to matched controls, with ESLD patients in the 
≥60 age group having a 48% deficit in visceral fat (compared to the 18-39 ESLD patients with only an 
8% deficit (p= <0.01)).   
Patients were grouped into three MELD groups (6-19, 20-30, 31-40) with approximately equal 
number of patients in each group (32, 33, and 25). [Table 5]  Only serum albumin differed significantly 
between MELD groups, with more severe disease correlating with lower serum albumin (p<0.001). 
Muscle mass, subcutaneous fat, and visceral fat indices were not significantly different between MELD 
groups.     
DISCUSSION 
The present study supports previous research that there are substantial nutritional deficits in the 
ESLD population that are not adequately measured by laboratory testing. Sarcopenia, or decreased muscle 
mass, is an important predictor of patient outcomes in the ESLD patient population.[8, 13-15]  Studies 
have recently proposed cut-off values for specific populations to define and quantify the severity of 
sarcopenia using CT or magnetic resonance imaging.[5, 8, 14, 15, 24-28] These cut-off ranges are often 
ambiguous, such as the lowest quartile, and not based on clinical outcomes. The present study avoids the 
ambiguity of population specific cut-offs by using a case-control design where each ESLD patient is 
compared to a healthy gender-age-BMI-matched control. This study demonstrates that ESLD patients 
experience sarcopenia and decreased visceral fat while maintaining a comparable amount of subcutaneous 
fat when compared to healthy age-gender-BMI-matched controls.  
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The subgroup analyses suggest that the groups at risk for the most profound sarcopenia are 
females, the elderly, and patients with BMI <25. A previous study suggested the presence of gender 
specific body compositional changes showing that muscle wasting may be more severe in males, while 
females have more severe fat deficits with preserved muscle volume.[6] In the present study females had 
a lower muscle mass index and visceral fat index; however, the percent difference between male cases 
and controls and female cases and controls was not significantly different for all three indices.  This 
suggests that body compositional changes may actually be similar among women and men with ESLD.  
Other studies have recognized this by reporting gender specific sarcopenia cut-off values for males and 
females.  Though sarcopenia may not be as prevalent in women as originally thought, the risk for 
complications in sarcopenic women may be greater than in sarcopenic men. One study found that 43% of 
women classified as sarcopenic experienced major complications, while only 10% of non-sarcopenic 
women experienced complications (p<0.01).[29] 
The elderly were also identified as a population at high risk for developing severe sarcopenia. 
ESLD patients over the age of 60 had the lowest muscle mass index of any age group and the greatest 
deficit of visceral fat when compared to healthy controls. One explanation for the increased risk of 
sarcopenia may be an additive affect of multiple physiological mechanisms such as malnutrition and 
increased myostatin thought to be associated with aging, as well as the mechanisms associated with liver 
failure. The visceral fat index trended upward with increasing age, though the visceral fat deficit for 
diseased patients trended downward.  Patients with ESLD may not store as much visceral fat as healthy 
individuals as they age, or this reserve may be mobilized more readily in the elderly in response to 
disease.   
ESLD patients with lower BMI had more severe sarcopenia.  This finding is contrary to the idea 
of sarcopenic obesity that has been described in many populations. The present study suggests that 
sarcopenic obesity is not present in the adult ESLD population. Increased BMI may have a protective 
effect on the development of sarcopenia.  This finding of increased muscle mass with increasing BMI 
may also help to explain the obesity paradox, where obese, or overweight, patients with end organ failure 
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have better post-surgical outcomes.  Visceral fat was found to be significantly different between the 
different BMI and age groups (p=0.02, <0.001, respectively).  One study found that the ratio between 
visceral and subcutaneous fat might be an important predictor of mortality with increased visceral fat 
being associated with increased post-transplant mortality.[26] This also supports the obesity paradox, as 
those with higher BMI were more deficient in visceral fat and less deficient in subcutaneous fat.  
MELD did not correlate well with muscle mass, subcutaneous fat, or visceral fat indices. A 
previous study also suggested that muscle mass was not associated with MELD.[12] One study suggests 
sarcopenia may only be associated with mortality in less severe liver disease (MELD<15).[15] Utilization 
of sarcopenia as a prognostic factor, in addition to MELD, may be an important clinical indicator of 
successful transplantation and wise allocation of organs. However, muscle quality as measured by 
strength or stamina may be more predictive of mortality than simple muscle mass. Several measure of 
strength have been reported including hand grip strength, Short Physical Performance Battery, and muscle 
density, the six minute walk test and the 5 meter walk test. Unfortunately, the present study did not 
address the issue of muscle quality or mortality.[30]  
In conclusion, this study uses a carefully matched case-control design to assess nutritional deficits 
in the ESLD population using objective CT measures. CT measures provide novel insight into frailty and 
sarcopenia that cannot be understood with the standard serum markers of nutrition, albumin and protein. 
Objectively assessing a patient’s level of sarcopenia may assist in clinical management, as well as risk 
stratification in choosing patients as transplant candidates. This appears to be especially true in certain 
patient populations such as the elderly, morbidly obese, female and those with low BMI.    
 
  
Figure legend.  
A. Cross sectional image of the abdomen at the L2-L3 disc interspace. The picture illustrates the location 
of the measures taken to assess (B) psoas area, and (C) visceral (perinephric) and (D) subcutaneous fat. 
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Table 1. Comparison of patients with end-stage liver disease and healthy controls. 
  
  Controls End stage liver disease p-value 
OVERALL (number (%)) 90 90 
 Demographics 
      
     MELD (mean) 22 
     Gender: Male 104 (58%) 104 (58%) 1 
     Age (years, median(range)) 46 45 0.84 
     Body mass index (median) 27.8 27.2 0.87 
 Laboratory measures 
      
     Serum albumin (g/dL) 3.6 2.9 <0.001 
     Total protein (g/dL) 6.5 6.5 0.72 
 Sarcopenia (group comparison) 
      
     Psoas area index (median) 
         Grouped comparison 5.2 4.2 <0.001 
         Matched comparison (% difference) -19% 
Measures of body fat (group comparison) 
      
     Subcutaneous fat index (median) 
         Grouped comparison 59.1 55.1 0.35 
         Matched comparison (% difference) -1% 
     Perinephric fat index (median) 
         Grouped comparison 11.4 7.1 <0.001 
         Matched comparison (% difference) -13% 
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Table 4. Comparison of patients with end-stage liver disease and healthy controls 
stratified by MELD score 
 
  
  Controls End stage liver disease p-value* 
 
Study patient age 
    18 to 39 30 to 49 50 to 59  >60 
Number 90 64 48 46 22 
 Laboratory measures 
            
     Serum albumin (g/dL) 3.6 2.7 2.9 3.1 2.6 0.56 
     Total protein (g/dL) 6.5 6.4 6.3 6.5 6.7 0.33 
 Sarcopenia (group comparison) 
            
     Psoas area index (median) 
         Grouped comparison 5.2 4.3 4.1 4.4 3.6 0.05 
         Matched comparison (% difference)   -21% -26% -8% -25 0.19 
Measures of body fat (group comparison) 
          
     Subcutaneous fat index (median) 
         Grouped comparison 59.1 48.1 55.8 62.7 51.7 0.81 
         Matched comparison (% difference) 4% 8% -2% -11 0.66 
     Perinephric fat index (median) 
         Grouped comparison 11.4 5.3 6.8 8.7 9 <0.001 
         Matched comparison (% difference) -8% -26% -12% -48 <0.01 
* For difference among age groups 
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Table 5. Comparison of patients with end-stage liver disease and healthy controls 
stratified by MELD score 
 
  
  Controls End stage liver disease 
  
p-value* 
 
Body mass index 
    < 25 25 to 29 30 to 34 >35   
Number 90 64 60 36 20 
 Laboratory measures 
            
     Serum albumin (g/dL) 3.6 2.9 2.9 3.1 2.5 0.37 
     Total protein (g/dL) 6.5 6.5 6.5 6 6.8 0.49 
 Sarcopenia (group comparison) 
            
     Psoas area index (median) 
         Grouped comparison 5.2 3.2 4.4 4.8 4.9 0.03 
         Matched comparison (% difference) -29% -22% -16% 9% 0.08 
Measures of body fat (group comparison) 
          
     Subcutaneous fat index (median) 
         Grouped comparison 59.1 37.1 51.4 77.2 121.5 <0.001 
         Matched comparison (% difference) -11% 7% -8% 7 0.29 
     Perinephric fat index (median) 
         Grouped comparison 11.4 5.6 7.4 8.3 11 0.02 
         Matched comparison (% difference) -12% -12% -27% -34% 0.29 
* For difference among body mass index groups 
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Table 2. Comparison of patients with end-stage liver disease and healthy controls 
stratified by MELD score 
 
  
  Controls End stage liver disease p-value* 
  
  
MELD Score 
    6 to 19 20 to 30 30 to 40   
Number 90 32 33 25 
 Laboratory measures 
          
     Serum albumin (g/dL) 3.6 3.1 2.7 2.6 <0.001 
     Total protein (g/dL) 6.5 6.5 6.8 5.7 0.28 
 Sarcopenia (group comparison) 
    
     Psoas area index (median) 
         Grouped comparison 5.2 4.2 4.1 4.2 0.66 
         Matched comparison (% difference) -28% -19% -19% 
Measures of body fat (group comparison) 
  
     Subcutaneous fat index (median) 
         Grouped comparison 59.1 66.6 52.6 49.5 0.54 
         Matched comparison (% difference) -10% 5% 15% 
     Perinephric fat index (median) 
         Grouped comparison 11.4 7.1 5.8 7.3 0.76 
         Matched comparison (% difference) -12% -13% -23% 
* For difference among MELD score groups 
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Table 3. Comparison of patients with end-stage liver disease and healthy controls 
stratified by MELD score 
 
  
  Controls End stage liver disease p-value* 
 
Gender 
    Male Female   
Number 90 52 38 
 Laboratory measures 
        
     Serum albumin (g/dL) 3.6 2.8 2.9 0.25 
     Total protein (g/dL) 6.5 6.1 6.9 <0.01 
 
      
Sarcopenia (group comparison) 
        
     Psoas area index (median)       
         Grouped comparison 5.2 4.7 3.5 <0.001 
         Matched comparison (% difference)   -19% -17% 0.56 
        
Measures of body fat (group comparison) 
        
     Subcutaneous fat index (median)         
         Grouped comparison 59.1 51.4 69.1 <0.001 
         Matched comparison (% difference)   -1% 1% 0.38 
        
     Perinephric fat index (median)         
         Grouped comparison 11.4 8.4 6.3 <0.001 
         Matched comparison (% difference)   -19% -11% 0.17 
* For difference among gender groups 
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Research Highlights 
 
Key Points 
 
1. Compared to healthy controls, patients with end-stage liver disease have marked sarcopenia and loss 
of visceral fat, but similar subcutaneous fat. 
 
2. End-stage liver disease patients at highest risk for sarcopenia include the elderly, patients with low 
body mass index, and females. 
 
3. Severity of liver disease, as measured by model for end-stage liver disease score, is not correlated 
with degree of sarcopenia. 
 
4. The severity of nutritional deficits associated with end-stage liver disease are not adequately 
represented by serum albumin and protein levels, though serum albumin does correlate with model for 
end-stage liver disease score.  
 
